Clinical Trials Logo
  1. Home
  2. Anosmia
  3. NCT04657809

Clinical Assessment of Insulin Fast Dissolving Film in Treatment of Post Infection Anosmia

Anosmia Clinical Trial

Official title:
"Insulin Fast Dissolving Film for Intranasal Delivery Via Olfactory Region, a Promising Approach for the Treatment of Anosmia in COVID 19 Patients: Design, In-vitro Characterization and Clinical Evaluation."

Clinical Trial Summary

The study aimed to investigate the efficacy of insulin in a new dosage form ( fast dissolving film) in treatment of anosmia in patients post infested with Covid-19. The study implication based in two methods evaluations 1. Threshold test 2. identification test.

Clinical Trial Description

This study was designed to improve smell disorders after corona infection that is very anxious for all patients. Inclusion criteria were loss of smell, post covid-19 infection, age from 18 to 70 years and accept sharing and follow up. The application of dosage form by ENT specialist at otorhinolaryngology clinic at Minia University hospital. Dose was 100iu of insulin 3 times weekly for 4 weeks. The new dosage form with insulin was compared with a placebo to ensure statistical improvement. The tests were performed in each visit. Primary outcome was the improvement of smell sensors in those patients ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04657809
Study type Interventional
Source Deraya University
Contact
Status Completed
Phase Phase 2
Start date October 1, 2020
Completion date March 20, 2021
View Details
See also
  Status Clinical Trial Phase
Terminated NCT04964414 - Treatment of Pediatric Patients That Lost Sense of Smell Due to COVID-19 Phase 1/Phase 2
Completed NCT05445921 - Stellate Ganglion Block for COVID-19-Induced Olfactory Dysfunction Phase 1/Phase 2
Completed NCT05812209 - Stellate Ganglion Block to Treat Long COVID 19 Case Series
Withdrawn NCT02179554 - Does Cardiopulmonary Bypass Change Olfaction?
Completed NCT04957563 - Clinical Utility of Olfactory Rehabilitation: Treatment for Pacients With Neurosensorial Anosmia N/A
Terminated NCT03680911 - NAC for Head Trauma-induced Anosmia Phase 3
Completed NCT04853836 - Olfactory Disfunction and Co-ultraPEALut Phase 4
Recruiting NCT05040659 - Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2
Recruiting NCT05562050 - Characteristics of the Anosmic Olfactory Mucosa
Completed NCT05152030 - The Clinical Applicability of the 'TIB' Olfactory Test Device
Recruiting NCT05384561 - Olfactory Training as a Treatment for Olfactory Dysfunction Post COVID-19 N/A
Enrolling by invitation NCT04764981 - Olfactory Training for Olfactory Dysfunction After Coronavirus Disease - 19 (COVID-19) N/A
Withdrawn NCT04408391 - Brain MRI Imaging in Patients With SARS-Cov2 (COVID-19) Infection With or Without Anosmia
Completed NCT04361474 - Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity Phase 3
Completed NCT03990766 - Smell Changes & Efficacy of Nasal Theophylline Phase 2
Completed NCT04797936 - BNO 1030 Extract (Imupret) in the Treatment of Mild Forms of COVID-19 Phase 4
Recruiting NCT04528329 - Anosmia and / or Ageusia and Early Corticosteroid Use Phase 4
Completed NCT04789499 - Smell in Covid-19 and Efficacy of Nasal Theophylline Phase 2
Recruiting NCT04384042 - Malaysian COVID-19 Anosmia Study (Phase 2) - A Nationwide Multicentre Case-Control Study
Completed NCT04390165 - Malaysian COVID-19 Anosmia Study (Phase 1) - A Nationwide Multicentre Cross-Sectional Study